Form 4: Immunic Inc. Executive Jason Tardio Reports Stock Option Grant

Immunic Inc.'s President and COO, Jason Tardio, was granted stock options for 157,500 shares on December 4, 2024.

Summary

• Jason Tardio, President and COO of Immunic Inc., received stock options for 157,500 shares on December 4, 2024.
• The exercise price of these options is $1.25 per share.
• The options vest over a period of 48 months, with 25% vesting on the first anniversary of the grant date and the remainder vesting monthly over the following 36 months.
• The options expire on December 4, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no indications of negative sentiment.

Positives

• The grant of stock options to a key executive like the President and COO can be seen as an incentive to align their interests with the company's long-term success.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The value of the stock options is dependent on the future performance of Immunic Inc.'s stock price.
• If the stock price does not increase above the exercise price of $1.25, the options may not be valuable to the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The vesting schedule of 25% after one year and the remainder monthly over the following 36 months is a typical vesting schedule for stock options.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign of management's commitment to the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, Immunic Inc., IMUX, Jason Tardio, vesting